Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
  • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Definitions

• This invention relates to novel pharmaceutical compositions containing an angiotensin-II receptor antagonist from a selected class in combination with a calcium channel blocker from a selected class useful for the treatment of hypertension and for the treatment of congestive heart failure.
• the selected class of angiotensin-II receptor antagonists and the selected class of calcium channel blockers essential as component parts of the novel compositions of this invention are compounds already known in the art as antihypertensive agents.
• Angiotensin-II receptor antagonists useful in compositions of the invention are included in those compounds disclosed in published European Published application 0 324 377 the disclosure of which is
• Calcium channel blockers useful in the compositions of this invention are selected from the group consisting of diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine,
• verapamil verapamil, gallopamil and tiapamil.
• compositions of this invention contain a calcium channel blocker of the group defined above in combination with an angiotensin-II receptor antagonist compound of the following formula:
• R 1 is CO 2 H; NHSO 2 CF 3 and
• R 2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;
• R 3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon
• R 4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
• R 5 is -(CH 2 ) m OR 7 ; -
• R 6 is H, alkyl of 1 to 5 carbon atoms or OR 10 ;
• R 7 is H or alkyl of 1 to 4 carbon atoms
• R 8 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
• R 9 is CF 3 , alkyl of 1 to 6 carbon atoms or phenyl
• R 10 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of
• n 1 to 5 or a pharmaceutically acceptable salt thereof.
• Preferred compounds of the above formula are those in which R 1 is
• R 2 is H.
• Illustrative compounds of this preferred scope are:
• the potential antihypertensive effects of the combination of compounds of this invention may be demonstrated by administering the combination of active compounds to conscious spontaneously hypertensive rats. Rats received either orally or intravenously a dose of 0.1-30 mg/kg of the desired calcium channel blocker, or a dose of 0.1-30 mg/kg of the desired angiotensin-II receptor antagonist, or a combination of the two doses of the calcium channel blocker and the angiotensin-II receptor antagonist.
• Arterial blood pressure is
• hypertension are also of value in the management of acute and chronic congestive heart failure.
• These combinations also be expected to be useful in the treatment of secondary hyperaldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and secondary pulmonary hypertension, renal failure such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, end stage renal disease, renal transplant therapy, and the like, renal vascular hypertension, left ventricular dysfunction, diabetic retinopathy and in the management of vascular disorders such as migraine, Raynaud's disease, luminal hyperplasia, and to minimize the atherosclerotic process.
• administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
• administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
• administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
• administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
• administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
• administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
• administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-
• parenteral i.e., subcutaneous, intravenous
• administration can be by the oral route.
• the combinations of compounds can be administered by any conventional means available for use in
• an angiotensin-II antagonist and calcium channel blocker can be combined with other therapeutic agents, either as individual therapeutic agents or in a combination with additional therapeutic agents.
• an angiotensin-II antagonist and calcium channel blocker can be combined with other therapeutic agents.
• antihypertensives and/or diuretics and/or angiotensin converting enzyme inhibitors such as amiloride
• guanethidene sulfate hydralazine hydrochloride, hydrochlorothiazide, metolazone, metoprolol tartate, methyclothiazide, methyldopa, methyldopate
• benzthiazide quinethazone, ticrynafan, triamterene, acetazolamide, aminophylline, cyclothiazide, ethacrynic acid, furosemide, merethoxylline procaine, sodium ethacrynate, captopril, delapril hydrochloride,
• enalapril enalaprilat, fosinopril sodium, lisinopril, pentopril, quinapril hydrochloride, ramapril, teprotide, zofenopril calcium, diflusinal and the like.
• the combinations of active compounds can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard
• a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
• compositions of the invention may contain from 10 to 300 mg of the desired calcium channel blocker and 1 to 100 mg of the angiotensin-II receptor antagonist per unit dose one or more times daily.
• the active ingredients can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs syrups, and suspensions. They can also be administered parenterally, in sterile liquid dosage forms.
• Gelatin capsules contain the active ingredients and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours.
• Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective
• Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
• water a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
• saline aqueous dextrose (glucose)
• glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
• Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
• suitable stabilizing agents such as sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite
• bisulfite, sodium sulfite, or ascorbic acid are suitable stabilizing agents.
• citric acid and its salts and sodium EDTA are also used.
• parenteral solutions can contain
• preservatives such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
• Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field. Useful pharmaceutical dosage-forms for
• a large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each as with 100 milligrams of powdered active ingredients, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
• a mixture of active ingredients in a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil
• the dosage unit is 100 milligrams of active ingredients, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose.
• Appropriate coatings may be applied to increase the dosage unit.
• administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.
• An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredients, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=24814683

Family Applications (1)

Country Status (11)

Families Citing this family (23)

Family Cites Families (4)

• 1992
  • 1992-05-13 NZ NZ242724A patent/NZ242724A/xx not_active IP Right Cessation
  • 1992-05-14 IL IL10185892A patent/IL101858A/en not_active IP Right Cessation
  • 1992-05-14 WO PCT/US1992/003873 patent/WO1992020342A1/en not_active Application Discontinuation
  • 1992-05-14 CA CA002103276A patent/CA2103276A1/en not_active Abandoned
  • 1992-05-14 JP JP5500110A patent/JP2930252B2/ja not_active Expired - Lifetime
  • 1992-05-14 EP EP92912707A patent/EP0584250A1/en not_active Withdrawn
  • 1992-05-14 CZ CS932351A patent/CZ281570B6/cs not_active IP Right Cessation
  • 1992-05-14 MX MX9202243A patent/MX9202243A/es unknown
  • 1992-05-14 AU AU20269/92A patent/AU664375B2/en not_active Expired
  • 1992-05-15 ZA ZA923557A patent/ZA923557B/xx unknown
  • 1992-07-01 IE IE153492A patent/IE921534A1/en not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events